

Efektivitas uji saring antigen dan antibodi HCV untuk meningkatkan keamanan darah donor = The effectiveness of the screening of HCV antigen and antibodies to improve security blood donors

Pierlita Rini, author

Deskripsi Lengkap: <https://lib.ui.ac.id/detail?id=20404049&lokasi=lokal>

Abstrak

[ABSTRAK

Latar belakang. Uji saring darah donor dapat menurunkan risiko tertularnya infeksi HCV. Di Indonesia telah dilakukan uji saring terhadap antibodi HCV

dan RNA HCV. Uji saring terhadap Antigen-Antibodi belum dilakukan di

Indonesia. Antigen HCV biasanya ditemukan pada 0 sampai 20 hari setelah RNA HCV pertama muncul.

Anti-HCV dapat terdeteksi antara 10-40 hari

setelah antigen HCV terdeteksi. Atas dasar pemikiran bahwa antigen HCV

muncul didalam darah lebih dahulu daripada anti-HCV, maka penelitian yang

dilakukan ingin melihat apakah penggunaan reagensia serologi antigen-antibodi HCV dapat meningkatkan

keamanan darah dan apakah sensitivitas serta spesifisitasnya sudah memenuhi standard yang dikeluarkan

oleh Kementerian Kesehatan bila dibandingkan terhadap metoda NAT, yaitu sensitivitas 99,8% dan

spesifisitas 95%.

Metodologi. Pada penelitian ini dilakukan pemeriksaan pada 135 sampel darah donor yang terdiri dari 35 sampel positif dengan NAT HCV dan 100 sampel Positif dengan NAT HCV juga non reaktif terhadap HIV, HBsAg dan Sifilis dengan uji saring anti-HCV dengan metode CMIA, Ab-Ag HCV dengan metode ELISA dan bila ada perbedaan hasil pada pemeriksaan NAT HCV,

CMIA HCV dan ELISA Ag-Ab HCV dilakukan pemeriksaan dengan menggunakan imunoblot HCV.

Hasil. Dari 135 sampel, pada pemeriksaan ELISA Ag-Ab HCV terhadap 35 sampel positif RNA HCV menunjukkan hasil positif pada 35 sampel tersebut,

tetapi pada 100 sampel negatif RNA HCV terdapat 3 sampel reaktif dan 97 non

reaktif. Sedangkan pada 35 sampel positif RNA HCV dengan pemeriksaan

CMIA anti-HCV menunjukkan hasil reaktif pada 35 sampel dan pada 100 sampel negatif RNA HCV

terdapat 11 sampel reaktif dan 89 sampel non reaktif.

Sensitivitas dari perbandingan hasil pemeriksaan metoda NAT HCV dengan CMIA Ab-HCV adalah 100%,

spesifisitasnya adalah 89%. Sensitivitas dari perbandingan hasil pemeriksaan metoda NAT HCV dengan

ELISA Ag-Ab

HCV adalah 100%, spesifisitasnya adalah 97%.

Simpulan. Pemeriksaan Antigen-Antibodi HCV ELISA memenuhi kriteria

standar untuk digunakan sebagai uji saring darah donor. Pemeriksaan Antibodi

HCV CMIA tidak memenuhi kriteria standar untuk digunakan sebagai uji saring

darah donor.

<hr>

ABSTRACT

Background. Screening of donor blood may reduce the risk of transmission of HCV infection . In Indonesia

has been screened for HCV antibodies and HCV

RNA. Screened against the antigen-antibody has not been done in Indonesia.

HCV antigens commonly found in 0 to 20 days after HCV RNA first appears.

Anti-HCV can be detected between 10-40 days after HCV antigen was

detected. On the basis of the notion that HCV antigens appear in the blood earlier than the anti-HCV, the research done to see if the use of antigen-antibody reagents HCV serology can improve blood safety and whether the

sensitivity and specificity already meet the standards issued by the Ministry of Health when compared to NAT method, the sensitivity 99.8% and specificity of 95%. Methodology. In this study conducted checks on 135 blood samples from 35 donors comprising the NAT HCV positive samples and 100 samples positive by HCV NAT is also non-reactive to HIV, HBsAg and syphilis with anti-HCV

screening of the CMIA method, HCV Ab-Ag ELISA method and the

examination confirmed using immunoblot HCV HCV. Results. Of the 135 samples, the Ag-Ab ELISA against HCV 35 HCV RNA positive samples showed positive results in 35 samples, but at 100 HCV RNA negative samples contained 3 samples reactive and non-reactive 97. While the

35 HCV RNA positive samples with anti-HCV CMIA examination showed

reactive results on 35 samples and in 100 HCV RNA negative samples contained 11 samples 89 samples reactive and non-reactive. Sensitivity of the

results of the comparison method with CMIA HCV NAT-HCV Ab was 100%,

specificity was 89%. Sensitivity of the results of the comparison method of NAT HCV Ag-Ab ELISA with HCV was 100%, specificity was 97%. Conclusion. Examination of HCV Antigen-Antibody ELISA meet the

standard criteria for use as a screening of donor blood. Examination of HCV antibodies

CMIA does not meet the standard criteria for use as a screening of donor blood.; Background. Screening of donor blood may reduce the risk of transmission of HCV infection. In Indonesia has been screened for HCV antibodies and HCV

RNA. Screened against the antigen-antibody has not been done in Indonesia.

HCV antigens commonly found in 0 to 20 days after HCV RNA first appears.

Anti-HCV can be detected between 10-40 days after HCV antigen was

detected. On the basis of the notion that HCV antigens appear in the blood earlier than the anti-HCV, the research done to see if the use of antigen-antibody reagents HCV serology can improve blood safety and whether the

sensitivity and specificity already meet the standards issued by the Ministry of Health when compared to NAT method, the sensitivity 99.8% and specificity of 95%. Methodology. In this study conducted checks on 135 blood samples from 35 donors comprising the NAT HCV positive samples and 100 samples positive by HCV NAT is also non-reactive to HIV, HBsAg and syphilis with anti-HCV

screening of the CMIA method, HCV Ab-Ag ELISA method and the

examination confirmed using immunoblot HCV HCV. Results. Of the 135 samples, the Ag-Ab ELISA against HCV 35 HCV RNA positive samples showed positive results in 35 samples, but at 100 HCV RNA negative samples contained 3 samples reactive and non-reactive 97. While the

35 HCV RNA positive samples with anti-HCV CMIA examination showed

reactive results on 35 samples and in 100 HCV RNA negative samples contained 11 samples 89 samples reactive and non-reactive. Sensitivity of the

results of the comparison method with CMIA HCV NAT-HCV Ab was 100%, specificity was 89%. Sensitivity of the results of the comparison method of NAT HCV Ag-Ab ELISA with HCV was 100%, specificity was 97%. Conclusion. Examination of HCV Antigen-Antibody ELISA meet the standard criteria for use as a screening of donor blood. Examination of HCV antibodies CMIA does not meet the standard criteria for use as a screening of donor blood., Background. Screening of donor blood may reduce the risk of transmission of HCV infection . In Indonesia has be screened for HCV antibodies and HCV RNA . Screened against the antigen - antibody has not been done in Indonesia . HCV antigens commonly found in 0 to 20 days after HCV RNA first appears . Anti - HCV can be detected between 10-40 days after HCV antigen was detected . On the basis of the notion that HCV antigens appear in the blood earlier than the anti - HCV , the research done to see if the use of antigen - antibody reagents HCV serology can improve blood safety and whether the sensitivity and specificity already meet the standards issued by the Ministry of Health when compared to NAT method , the sensitivity 99.8 % and specificity of 95 % . Methodology. In this study conducted checks on 135 blood samples from 35 donors comprising the NAT HCV positive samples and 100 samples positive by HCV NAT is also non- reactive to HIV , HBsAg and syphilis with anti - HCV screening of the CMIA method, HCV Ab-Ag ELISA method and the examination confirmed using immunoblot HCV HCV . Results. Of the 135 samples, the Ag-Ab ELISA against HCV 35 HCV RNA positive samples showed positive results in 35 samples, but at 100 HCV RNA negative samples contained 3 samples reactive and non- reactive 97. While the 35 HCV RNA positive samples with anti-HCV CMIA examination showed reactive results on 35 samples and in 100 HCV RNA negative samples contained 11 samples 89 samples reactive and non reactive. Sensitivity of the results of the comparison method with CMIA HCV NAT-HCV Ab was 100%, specificity was 89%. Sensitivity of the results of the comparison method of NAT HCV Ag-Ab ELISA with HCV was 100%, specificity was 97%. Conclusion. Examination of HCV Antigen-Antibody ELISA meet the standard criteria for use as a screening of donor blood. Examination of HCV antibodies CMIA does not meet the standard criteria for use as a screening of donor blood.]